Tamsulosin Hydrochloride + FinasterideThird Party Manufacturing in India

Tamsulosin Hydrochloride plus Finasteride is a fixed-dose combination that provides comprehensive medical management of benign prostatic hyperplasia through two distinct and complementary mechanisms targeting both the dynamic and static components of bladder outlet obstruction. Tamsulosin is a highly selective antagonist of alpha-1A adrenergic receptors located predominantly in the prostatic smooth muscle, bladder neck, and prostatic urethra. By competitively blocking the binding of endogenous catecholamines to these receptors, tamsulosin inhibits sympathetic nervous system-mediated contraction of prostatic smooth muscle, thereby reducing urethral resistance and improving urine flow. This functional alpha-blockade produces rapid symptomatic relief within 2 to 6 hours of administration, addressing the dynamic or tone-related component of BPH. Finasteride is a competitive, selective inhibitor of the type 2 isoform of 5-alpha reductase, the intracellular enzyme that converts testosterone to the more potent androgen dihydrotestosterone within the prostate gland. By inhibiting type 2 5-alpha reductase, finasteride reduces serum DHT levels by approximately 70 percent and intraprostatic DHT levels by 85 to 90 percent, depriving prostate epithelial cells of the primary growth stimulus. This results in involution of prostatic glandular tissue, a progressive reduction in prostate volume of 15 to 25 percent over 6 to 12 months, and a corresponding improvement in urinary flow and symptom scores. The combination of rapid symptomatic relief from tamsulosin with disease-modifying volume reduction from finasteride provides a therapeutic benefit superior to either component alone in patients with moderate to severe BPH and prostate enlargement.

Therapeutic Uses

Tamsulosin Hydrochloride + Finasteride is prescribed for the treatment of:

• Benign Prostatic Hyperplasia with Prostatic Enlargement: This combination is indicated for men with symptomatic BPH and prostate volumes of 40 mL or greater, where dual mechanism therapy provides superior symptom reduction and disease modification compared to monotherapy.
• Reduction of Acute Urinary Retention Risk: Long-term combination therapy with tamsulosin and finasteride reduces the risk of acute urinary retention and the need for transurethral resection of the prostate or other surgical interventions.
• Lower Urinary Tract Symptoms Due to BPH: Patients with moderate to severe LUTS secondary to BPH experience greater improvement in International Prostate Symptom Scores, peak urinary flow rate, and quality of life indices with combination therapy.
• Long-Term Medical Management of BPH: The combination is suitable for patients requiring sustained BPH treatment, with tamsulosin providing immediate symptom relief while finasteride progressively reduces prostate volume over months of continuous therapy.

Why Manufacturers Choose Tamsulosin Hydrochloride + Finasteride

The tamsulosin plus finasteride fixed-dose combination is a well-established medical therapy for BPH, prescribed extensively by urologists and general practitioners managing symptomatic prostate enlargement in ageing male populations. Available as 0.4 mg + 5 mg extended-release tablets, this combination allows for once-daily dosing with the convenience of a single tablet. Indian manufacturers benefit from the large and rapidly growing geriatric demographic, patent-expired status of both components enabling competitive generic pricing, and established prescribing habits across both specialty and primary care channels. The extended-release formulation of tamsulosin in this combination reduces plasma concentration variability and improves tolerability compared to immediate-release formulations. Well-understood API characteristics, cost-efficient bilayer tableting technology, and strong demand in both domestic PCD franchise and regulated export markets make this combination a volume driver in the urology segment. This makes Tamsulosin + Finasteride one of the most sought-after combination products for third party manufacturing in India, with consistent demand from PCD franchise operators.